Baker Bros. Advisors LP Adaptimmune Therapeutics PLC Transaction History

Baker Bros. Advisors LP

$7.52 Billion
Q2 2024

A detailed history of Baker Bros. Advisors LP transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Baker Bros. Advisors LP holds 2,343,695 shares of ADAP stock, worth $2.3 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

2,343,695

Previous 10,787,022 78.27%

Holding current value

$2.3 Million

Previous $17 Million 86.53%

% of portfolio

0.03%

Previous 0.22%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.83 - $1.47 $7.01 Million - $12.4 Million	-8,443,327 Reduced 78.27%	2,343,695 $2.3 Million
Q1 2024 May 15, 2024	SELL	$0.7 - $1.75 $127,581 - $318,955	-182,260 Reduced 1.66%	10,787,022 $17 Million
Q2 2023 Aug 14, 2023	BUY	$0.9 - $1.51 $1.02 Million - $1.72 Million	1,138,405 Added 11.58%	10,969,282 $10.1 Million
Q4 2020 Feb 16, 2021	BUY	$4.0 - $9.2 $14 Million - $32.2 Million	3,500,523 Added 55.3%	9,830,877 $53 Million
Q3 2020 Nov 16, 2020	SELL	$7.66 - $10.78 $2.64 Million - $3.72 Million	-344,827 Reduced 5.17%	6,330,354 $50.5 Million
Q2 2020 Aug 14, 2020	BUY	$2.58 - $12.1 $7.7 Million - $36.1 Million	2,984,874 Added 80.88%	6,675,181 $66.8 Million
Q1 2020 May 15, 2020	BUY	$1.2 - $4.52 $4.43 Million - $16.7 Million	3,690,307 New	3,690,307 $10 Million
Q3 2018 Nov 14, 2018	SELL	$8.27 - $13.56 $827,000 - $1.36 Million	-100,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$4.93 - $8.93 $493,000 - $893,000	100,000	100,000 $819,000

Others Institutions Holding ADAP

# of Institutions

Shares Held

152M

Call Options Held

78.5K

Put Options Held

36.5K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $160M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.

Account

Baker Bros. Advisors LP Adaptimmune Therapeutics PLC Transaction History